Travere Therapeutics Stock Soars Pre-Market After FDA Waives Need For An Advisory Committee Meeting On Its Kidney Disorder Drug Application

2025-09-10 08:12:10

(MENAFN- AsiaNet News)

Travere Therapeutics (TVTX) on Wednesday said that the U.S. Food and Drug Administration informed the company that it has waived the need for an advisory committee meeting regarding its application for Filspari in treating focal segmental glomerulosclerosis (FSGS).

The FDA is expected to decide on the company's application by January 13, 2026. If approved, Filspari would be the first medication indicated for FSGS, a rare and serious kidney disorder driven by proteinuria that leads to progressive kidney function loss and kidney failure, the company said.

Shares of the company soared 16% in the pre-market session.

Get updates to this developing story <directly on Stocktwits.

MENAFN10092025007385015968ID1110042945

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.